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Abstract
Background: Respiratory syncytial virus (RSV) frequently causes acute lower respiratory infection in children under
5, representing a high burden in Gavi-eligible countries (mostly low-income and lower-middle-income). Since
multiple RSV interventions, including vaccines and monoclonal antibody (mAb) candidates, are under development,
we aim to evaluate the key drivers of the cost-effectiveness of maternal vaccination and infant mAb for 72 Gavi
countries.
Methods: A static Multi-Country Model Application for RSV Cost-Effectiveness poLicy (MCMARCEL) was developed
to follow RSV-related events monthly from birth until 5 years of age. MCMARCEL was parameterised using country-
and age-specific demographic, epidemiological, and cost data. The interventions’ level and duration of effectiveness
were guided by the World Health Organization’s preferred product characteristics and other literature. Maternal
vaccination and mAb were assumed to require single-dose administration at prices assumed to align with other
Gavi-subsidised technologies. The effectiveness and the prices of the interventions were simultaneously varied in
extensive scenario analyses. Disability-adjusted life years (DALYs) were the primary health outcomes for cost-effectiveness,
integrated with probabilistic sensitivity analyses and Expected Value of Partially Perfect Information analysis.
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Results: The RSV-associated disease burden among children in these 72 countries is estimated at an average of 20.8 million
cases, 1.8 million hospital admissions, 40 thousand deaths, 1.2 million discounted DALYs, and US$611 million discounted
direct costs. Strategy ‘mAb’ is more effective due to its assumed longer duration of protection versus maternal vaccination,
but it was also assumed to be more expensive. Given all parameterised uncertainty, the optimal strategy of choice tends to
change for increasing willingness to pay (WTP) values per DALY averted from the current situation to maternal vaccination
(at WTP >US$1000) to mAB (at WTP >US$3500). The age-specific proportions of cases that are hospitalised and/or die cause
most of the uncertainty in the choice of optimal strategy. Results are broadly similar across countries.
Conclusions: Both the maternal and mAb strategies need to be competitively priced to be judged as relatively cost-
effective. Information on the level and duration of protection is crucial, but also more and better disease burden
evidence—especially on RSV-attributable hospitalisation and death rates—is needed to support policy choices when
novel RSV products become available.
Keywords: Respiratory syncytial virus, Cost-effectiveness analysis, Maternal vaccination, Monoclonal antibody, Disease
burden, Expected Value of Partially Perfect Information, Probabilistic sensitivity analysis, Low-income countries and
lower-middle-income countries
Introduction
Respiratory syncytial virus (RSV) is one of the major
causes of acute lower respiratory infection (ALRI), result-
ing frequently in hospitalisation (and sometimes death) in
children under the age of 5 years [1, 2]. A recent system-
atic review estimated that 33 million RSV-ALRI cases and
118 thousand deaths occur annually in children under 5,
of which 22 million cases and 103 thousand deaths are in
low-income countries (LICs) and lower-middle-income-
countries (LMICs) [2].
The currently available prophylactic RSV intervention
(palivizumab) consists of a monthly injection over the course
of the RSV season. It is only recommended for high-risk
groups and only used in a few countries, partly because it is
expensive [3]. However, there are multiple maternal RSV
vaccine and monoclonal antibody (mAb) candidates under
clinical development [4]. The most advanced maternal vac-
cine candidate, NCT02624947 (Novavax), has completed the
phase 3 trial, but did not meet its primary endpoint of med-
ically significant RSV lower respiratory tract infection (LRTI)
[5, 6]. A new single-dose mAb candidate, MEDI8897 (Sanofi
Pasteur / MedImmune), has also completed the phase IIb
trial and met its primary endpoint of medically attended
LRTI due to RT-PCR-confirmed RSV [7, 8].
Passive immunisation through maternal immunisation
or monoclonal antibodies could potentially prevent RSV
disease after birth, by protecting vulnerable infants [9].
In most LMICs and LICs, the Expanded Programme on
Immunization (EPI) is well established, including paedi-
atric and neonatal (at birth) components, and the single-
dose RSV mAb, administered at birth, could be inte-
grated into existing prevention programmes. In recent
years, initiatives to administer inactive influenza vaccines
and pertussis vaccines to mothers during antenatal care
(ANC) visits have been successfully implemented in
many high-income countries. In LICs and LMICs, the
dramatic increase in the antenatal care (ANC) coverage
during the past decade renders feasible the implementa-
tion of the maternal RSV vaccination programme via the
ANC platform [10].
There are limited resources and funding available in
LICs and LMICs, which leads to inequitable access of vac-
cines in these countries. The investment decisions on vac-
cines need to be made both at the country and a multi-
country level. Gavi, the Vaccine Alliance, is an organisa-
tion that invests in vaccines to protect children’s lives and
health in LICs and LMICs. Every 5 years, Gavi develops a
new vaccine investment strategy (VIS) to prioritise the
vaccines made available to countries throughout their vac-
cine support programme. RSV interventions, including
both maternal vaccine and mAb, were considered as one
of the six prioritised vaccine programmes as part of Gavi
VIS for the 2021–2025 funding period [11].
The majority of LICs and LMICs have sparse or no
data to make decisions on RSV interventions, but studies
on RSV epidemiology and outcomes may represent a
costly endeavour in resource-strapped settings. There-
fore, it is imperative that a cost-effectiveness analysis of
RSV interventions carefully evaluates the uncertainty
and main drivers of implementation of RSV prophylaxis.
This enables identifying the value that additional data
can provide to reduce uncertainty. While RSV preven-
tion technologies are still in development, data can be
collected on its disease burden and epidemiology to in-
form decision-making once the technologies are avail-
able. In order to be informative at both the multi-
country (i.e. Gavi, WHO) and single country levels, this
analysis aims to identify the key drivers of the cost-
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effectiveness of potential maternal vaccination and infant
monoclonal antibody strategies against RSV in 72 of the
current and former Gavi-eligible countries.1
Methods
Model structure
A multi-country RSV impact model, MCMARCEL (Multi-
Country Model Application for RSV Cost-Effectiveness poL-
icy), was developed in the R environment (https://www.r-
project.org/), based on the concept of a published single-
country static cohort model [12]. It follows a cohort of chil-
dren monthly from birth to 5 years of age. This model was
customised towards computationally efficient, multi-country
applications in LIC and LMIC settings.
The model compared no RSV intervention with (1) univer-
sal RSV vaccination in the second/third trimester of preg-
nancy (henceforth ‘maternal’ strategy) and (2) universal RSV
monoclonal antibodies at birth (henceforth ‘mAb’ strategy).
The analysis is conducted from a health care payer’s perspec-
tive including only direct health care costs and effects.
The model structure is presented in Fig. 1. The transi-
tion probabilities depend on the country-specific and
age-specific (at a monthly resolution) RSV incidence rate
as well as the selected vaccine/mAb strategies.
Demographic data
The United Nations population projections in 2020 were
used to estimate live births for each country [13]. The
target population for the maternal strategy was calcu-
lated based on country-specific birth rates (net of still-
births) [14]. Country-specific mortality rates and life
expectancy by age are interpolated from the United Na-
tions database (which provides data at 5-year intervals)
[13], where we fit two linear curves to interpolate the
age-specific data (more details in Table 1).
Burden of disease
The disease burden of RSV-associated ALRI in children
under 5 in each country was retrieved from a recent system-
atic review [2]. Ten community-based studies reported age-
specific incidence in LMICs, but no community-based inci-
dence study from LICs was available. The studies were
pooled, and age-specific incidence was simulated from a gen-
eralised additive mixed-effects (Poisson) regression model.
Next, the percent of cases in each age group was calculated
for all LMICs. Lastly, we calculated the product of the per-
cent of cases in each age group times the country-specific
overall incidence in all children under 5 years of age in order
to estimate the total number of cases in each age group for
each country (both LMIC and LIC).
Among the 72 Gavi-eligible countries, only two studies
[21, 22] were identified where RSV-associated hospitalisation
probabilities (i.e. the risk of hospitalisation for someone with
RSV) were reported; however, one study in Bangladesh re-
ported only one referral to a tertiary hospital, but did not
specify whether it was RSV-associated [21]. We chose not to
include this study (Homaira et al.) in our base-case analysis,
because the study centres provided treatment and only re-
ferred patients to tertiary hospital if needed [21]. The hospi-
talisation probabilities were estimated using a generalised
additive mixed-effects (logistic) regression model based on
the only other study we identified, which was fit to data
from Kenya (Nokes et al. [22]). Consequently, our estimated
hospitalisation probability is based on less evidence (i.e. only
one study) than most of the other input parameters (which
are informed by at least two studies). To account for this
additional uncertainty, we doubled the standard deviation
from the uncertainty distribution around the estimated hos-
pitalisation probability. In the scenario analysis, we also used
1Cuba was excluded from the Gavi-eligible countries due to a lack of
country-specific data available to use.
Fig. 1 Model structure
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pooled hospitalisation probabilities, which were based on
both Nokes et al.’s and Homaira et al.’s studies [15, 21].
We found 10 studies in LIC and 19 studies in
LMIC that reported age-specific hospital case-fatality
ratio (hCFR) including at least three age groups.
Based on sensitivity analysis (see Additional file 1),
we based all hCFR rates on the LMIC data because
they provided a more informative age-specific pattern
in younger infants, consistent with the literature [1,
2]. We adopted the method from Shi et al. to calcu-
late the overall RSV-associated mortality by assuming
that the number of deaths in the community is on
average almost the same as the within-hospital mor-
tality [2]. As such, the overall RSV death rate = death
in hospital × a community-multiplication factor of
2.2 × adjustment factor of 0.9 to account for overlap-
ping influenza activity. More details on the methods
can be found in Additional file 1.
Resource use and costs
In the absence of RSV-specific data, pneumonia health care
seeking data were used to estimate the proportion of children
with RSV-associated ALRI who did not seek health care [16],
and estimates from neighbouring countries were used for
countries for which such data were not available.
Due to the absence of specific cost data for RSV-
associated ALRI in LICs and LMICs [23], we bridged
cost data for an outpatient visit, cost per bed-day in the
hospital, and length of stay in the hospital (LoS) for
pneumonia from a recent systematic review [17], as 60%
of the published studies on pneumonia costs were con-
ducted in South East Asia and Africa (covering 8 of the
72 countries). Country-specific outpatient and inpatient
data were used where possible. If multiple studies were
available for one country, meta-analysis (using a random
effect model) was performed to pool the evidence for
the country. For countries without data on LoS, we used
the mean of 5.8 days LoS reported for LICs and LMICs
[17].
In order to estimate the RSV treatment cost for coun-
tries without available data, we first compared treatment
costs predicted in the WHO CHOosing Interventions
that are Cost-Effective (WHO-CHOICE) database of
non-disease-specific country treatment costs (outpatient
costs at primary hospital level and inpatient costs at sec-
ondary hospital level) with the cost data reported from
Table 1 Data input summary
Parameter Description Uncertainty
Demographic data Population projection in 2020 [13]
Under-1 and under-5 mortality, life expectancy
[13], and stillbirth rate [14]
Uncertainty was not taken into account
RSV disease burden Interpolate the age-specific data (per month) and scale it per
country
• RSV incidence
• Hospitalisation
• Mortality among hospitalised patients (probability), then
multiply adjustment factor 2.2 × 0.9 for overall death in both
hospital and community settings
• Uncertainty around age-specific RSV incidence and hos-
pital mortality; for details, refer to Additional file 1
• Uniform distribution is assumed for the overall death
adjustment factor 2.2 (1.5–2.9) and influenza adjustment
factor 0.9 (0.8–1)
Immunisation
coverage
WHO BCG coverage 2016 as a proxy for both strategies Uncertainty was not taken into account
Efficacy 70% (50–90%) [15] Only for scenario analysis
Duration of
protection
Maternal, 5 months (3–6 months) [15]
mAb, 6 months (4–8 months) [12]
Only for scenario analysis
Health care seeking
probabilities
WHO reported children with suspected pneumonia taken to an
appropriate health provider (%) (range, 13% in Somalia to 92.3%
in Ukraine) as proxies for outpatient visits [16]
Uncertainty was not taken into account
Hospital length of
stay
Country-specific data, or 5.8 days (95% CI 5.3–6.4) if data were
unavailable [17]
Gamma distribution (alpha = 432.52, beta = 0.014)
Treatment cost for
outpatient and
hospitalisation
Country-specific data, with pneumonia costs as a proxy for
outpatients and hospitalisations, or adjusted from the WHO-
CHOICE data [18]
Gamma distribution (for details, refer to Additional file 1)
Intervention cost in
USD (including
delivery cost)
Maternal, $3 for one dose
mAb, $6 for one dose
Only for scenario analysis
Health outcome Duration of illness, 11.2 days (10.1–12.3) [19]
DALYs of moderate ALRI, 0.053 (0.032–0.074) [20]
DALYs of severe ALRI, 0.21 (0.139–0.298) [20]
Gamma distribution
Duration of illness (α = 398.3, β = 0.014)
DALYs of moderate ALRI (α = 24.5, β = 0.002)
DALYs of severe ALRI (α = 26.8, β = 0.008)
Discounting 3% for both costs and health outcomes Not applicable
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the eight countries, as the WHO-CHOICE predictions
are not disease specific. We found that the pneumonia
treatment costs reported in the literature were 20-fold
and 3-fold higher than the WHO-CHOICE predicted
country-specific outpatients and inpatient costs, respect-
ively [18]. Consequently, adjustment factors were calcu-
lated (one for outpatient and one for inpatient costs),
with which the WHO-CHOICE costs were multiplied
(see Additional file 1 for more details).
All cost data were inflated to 2016 US dollar (USD)
values using local currency inflators and convertors from
the World Bank, based on the ‘first inflate, then convert’
principle [24]. This implies that costs reported in USD
were first converted back to their local currency value
(in the reported year) before inflation and reconversion.
Primary health outcome
Disability-adjusted life years (DALYs) were used as the
health utility metric. The base-case disability weights
were derived from the Global Burden of Disease Study
2010 [20]: the values for moderate infectious disease
(0.053) and severe acute episodes (0.21) were used for
non-hospitalised (both none care seeking or only pri-
mary/outpatient care) and hospitalised RSV cases,
respectively. The duration of illness was assumed to be
11.2 days (95% CI 10.1–12.3) based on a study con-
ducted in Kenya [19]. The years of life lost (YLL) due to
premature death were calculated from gender-specific
life expectancy in years at the age of death.
Intervention characteristics
In the base case, we used the WHO preferred product
characteristics and other literature to assume 70% effi-
cacy (range 50–90% for scenario analysis) for both the
maternal vaccine and mAb among the newborns [12, 15,
25, 26]. Recently, topline results of the first RSV mater-
nal immunisation phase 3 trial (Prepare™) have been
made public, and we applied the data in the scenario
analyses. Since the duration of protection data is not
available for the RSV interventions under study, we fur-
ther assumed that maternal vaccination offers 5 months
(3–6 months) and mAb 6months (4–8 months) protec-
tion after birth, but varied these assumptions extensively
in scenario analyses.
Country-specific Bacillus Calmette-Guérin (BCG)
coverage reported in 2016 was used as a proxy for both
strategies [16]. Both maternal and mAb strategies were
modelled under the assumption of a single-dose intra-
muscular injection. The intervention costs (procurement
and delivery costs) were assumed to be 3 USD for
maternal and 6 USD for mAb based on prices of other
Gavi-subsidised technologies [27], including both Gavi’s
and each country’s contribution irrespective of the rela-
tive share of each component to the total (i.e.
irrespective of the country’s position in the four Gavi
transitioning phases). These intervention cost assump-
tions—like all other assumptions—are made independ-
ently by the authors using the sources referenced in the
text. These assumptions do not reflect any current or fu-
ture pricing strategies of the pharmaceutical companies
taking part in the RESCEU project. A 5% wastage factor
was also applied [28].
Outcomes and scenario analyses
The number of RSV-associated cases, hospitalisations,
and deaths were presented without discounting, whereas
costs and DALYs were discounted at 3% per year ac-
cording to the WHO guideline. We identified the opti-
mal strategy for each country and for a range of societal
willingness to pay (WTP) values. The optimal strategy in
terms of cost-effectiveness refers to the strategy that
maximises the expected incremental net benefits (i.e. ei-
ther maternal vaccination, mAb, or no intervention).
Additionally, we estimated the degree of evidence in
favour of the optimal strategy, i.e. how certain we are
about the optimal strategy being ‘the best’ in terms of
cost-effectiveness [29].
Uncertainty around the price, efficacy, and duration of
the interventions, as well as the choice of data to inform
hospitalisation probability (i.e. using pooled Nokes
et al.’s and Homaira et al.’s studies instead of Nokes
et al. alone), was accounted for in scenario analyses [6].
All other uncertain aspects are accounted for in a
probabilistic way, i.e. 5000 random samples are drawn
from pre-defined uncertainty distributions for each input
parameter. The impact of probabilistic uncertainties on
the results was evaluated by calculating for each uncer-
tain input parameter the Expected Value of Partially Per-
fect Information (EVPPI). Our model code is available
via Zenodo (see reference [30]).
Results
Disease burden
The RSV-associated ALRI disease burden is substantial
in these 72 countries. Figure 2 illustrates the burden
using discounted DALYs per 1000 person-years (PY).
Senegal and Pakistan have the highest burden, whereas
Mongolia and Vietnam have the lowest DALYs per 1000
PY, because these countries experience the highest and
lowest RSV incidence rates, respectively (Fig. 2a).
The RSV-associated disease burden is estimated at
20.8 million cases [95% prediction interval (PI) 20.8–
20.9 million], leading to 1.8 million hospital admissions
[95% PI 0.4–4.9 million] and 40 thousand deaths [95%
PI 7–121 thousand] in the 72 countries combined. More
than one third of the RSV-associated disease burden oc-
curs in the first year of life. Using a 3% discount rate,
the treatment costs total $611 million [95% PI 327–1110
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Fig. 2 RSV-associated DALYs prior to RSV prevention and averted DALYs post-RSV prevention in 72 Gavi countries
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million] and the DALYs 1.2 million [95% PI 0.2–3.4 mil-
lion] (Table 2).
Effectiveness and cost-effectiveness
Maternal vaccination would prevent 1.2 million cases
[95% PI 0.6–1.9 million], 104 thousand hospital ad-
missions [95% PI 19–309 thousand], and 3 thousand
deaths [95% PI 1–11 thousand] in those countries. It
can avert 98 thousand discounted DALYs [95% PI
16–308 thousand] and 186 million USD [95% PI
144–206 million]. The mAb strategy would prevent
more cases and avert more discounted DALYs and
treatment costs (Fig. 2b, c and Table 2). However,
the mAb strategy would also result in higher dis-
counted net costs compared to the maternal strategy
due to the assumed higher intervention costs (6
USD vs. 3 USD). Country-specific results are pre-
sented in Additional file 1.
Fig. 3 Cost-effectiveness analysis of three interventions to prevent RSV prophylaxis.
The optimal strategy in terms of cost-effectiveness for each country and for a range of WTP values (0–30,000 USD per DALY averted) is indicated
by the colours (the current strategy is no intervention). The size of the markers indicates how certain we are about that strategy being optimal.
Countries are ranked by RSV incidence rate (ordered from high to low on the left Y-axis [incidence per 1000 person-year in brackets]) and
stratified by income group (LIC or LMIC, on the right Y-axis)
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Figure 3 presents the same information that is usually
presented by a cost-effectiveness acceptability frontier
(optimal strategy) and cost-effectiveness acceptability
curves (degree of uncertainty), but these presentation
formats do not allow to show several countries at once.
It demonstrates that as WTP per DALY averted in-
creases, the maternal and mAb strategies become the
optimal strategy for an increasing number of countries.
The maternal strategy would become the most cost-
effective strategy when the WTP value exceeds 1000
USD at the lower end (Armenia and Angola) or 3000
USD per DALY averted (Vietnam) at the upper end of
the country spectrum. The maternal strategy is the most
cost-effective strategy over a slightly larger range of
WTP values in LMICs (1000–8000 USD) than in LICs
(2000–6000 USD), but the between-country differences
within each income group are greater than the differ-
ences between the two income groups. Similarly, the
mAb strategy would be the optimal strategy if the WTP
value exceeds 3500 USD at the lower end (Armenia and
Angola) or 8000 USD per DALY averted (Vietnam) at
the higher end of the country spectrum.
The degree of certainty around the optimal strategy is
lower than 50% for the majority of countries, for WTP
values between 2500 USD and 7000 USD per DALY
averted. That is, for this range of WTP values, the prob-
ability that the optimal strategy results in the highest net
benefit is less than 50%. Hence, it is worthwhile to explore
what causes this substantial uncertainty (next section).
Uncertainty in the results
Expected Value of Partially Perfect Information
For each country, the EVPPI was calculated for each un-
certain input parameter and for a range of WTP values.
For the input parameters with high EVPPI values, it would
be (most) valuable to obtain more information in order to
identify the optimal strategy with more certainty. Senegal,
Vietnam, and Angola are shown in Fig. 4 as examples and
can be taken to represent the main differences between
countries. Generally, two peaks are observed in the EVPPI
graphs for all countries, which represent the WTP value
at which the optimal strategy changes from no interven-
tion (current practice) to the maternal, and from the ma-
ternal to the mAb strategy. At this WTP value, the
optimal strategy is most uncertain, and consequently,
obtaining more information is most valuable (i.e. the
EVPPI values are the highest). However, the precise WTP
values at which the EVPPI values peak, and the size of the
EVPPI values vary between countries.
For all countries, and for most of the WTP values con-
sidered, the uncertainty in the age-specific RSV hospital-
isation probability causes the highest uncertainty in the
choice of the optimal strategy. Additionally, the uncer-
tainty around RSV incidence rate, hospital case-fatality
ratio, and community case-fatality ratio is also among
the top influential factors for the choice of the optimal
strategy at all WTP values. A few countries are similar
to Angola, where the relevance of other parameters and
the ranking of importance depend on the WTP level. In
Angola, the uncertainty in the unit costs of outpatient
care is a stronger driver of uncertainty than hospitalisa-
tion probability at WTP values below 1000 USD per
DALY averted, because Angola has a higher outpatient
cost with a wider range of uncertainty compared to
other countries. In most other countries, uncertainty
around the average hospitalisation costs and outpatient
consultation costs does not influence the optimal strat-
egy to a great extent (see Additional file 1).
Scenario analysis: price, efficacy, and duration of protection
Price scenario analysis demonstrates that when the in-
cremental intervention cost per dose between maternal
Fig. 4 Expected Value of Partially Perfect Information, example of a Senegal, b Vietnam, and c Angola
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and mAb strategy is 1 USD (3 vs. 4 USD), the mAb is
the optimal strategy (Fig. 5a). In other words, an extra
month of protection is worth more than 1 USD.
When the incremental intervention cost increases to
8 USD (3 vs. 11 USD), the mAb only becomes opti-
mal at WTP values that exceed 15,000 USD per
DALY averted.
Scenario analysis on the intervention’s efficacy
shows that if the efficacy of both interventions is
50%, the maternal and mAb strategies require a
WTP value of 3000–5000 USD and 5500–11,500
USD, respectively, to become the optimal strategy.
However, if the efficacy of both interventions is 90%,
the switches from the no intervention to maternal
strategy occur at a WTP of 500–2500 USD, and
from the maternal to mAb strategy at 2500–6000
USD. That is, these changepoint WTP values decline
when efficacy increases, and vice versa (Fig. 6).
The uncertainties on interventions’ duration of protec-
tion are evaluated in Fig. 7. When the maternal and
mAb strategies only protect for 3 months and 4months,
respectively, neither of these become the optimal strat-
egy for a WTP value above 5000 USD per DALY averted
and the maternal strategy is unlikely to be the optimal
strategy at any WTP value (Fig. 7a). When maternal and
mAb strategies offer protection of 6 and 8months, re-
spectively, the maternal strategy has a probability of be-
ing the optimal strategy at WTP values of 1000 to 4000
USD, and the mAb strategy gradually becomes the opti-
mal strategy when the WTP value is above 5000 USD.
The results of scenario analyses using the pooled hos-
pital probability (Nokes et al. [22] and Homaira et al.
[21]) estimates, using no discounting and trial-based effi-
cacy, are presented in Additional file 1.
Discussion
Health economic evaluations for multiple interventions
and multiple countries are invaluable for decision-
makers involved in global initiatives. Our model applica-
tion, MCMARCEL, has been designed specifically to
simultaneously and efficiently evaluate the costs and ef-
fects of many countries and strategies, fully accounting
Fig. 5 Scenario analysis: the per-dose price difference between interventions and its impact on the optimal strategy.
Scenario assuming the incremental cost per dose between the maternal and mAb strategy a is 1 USD and b is 8 USD. The optimal strategy is
indicated by the colours (the current strategy is no intervention), and our certainty is indicated by the sizes of the markers. Countries are ranked
by RSV incidence rate (ordered from high to low on the left Y-axis [incidence per 1000 person-year in brackets]) and stratified by income group
(LIC or LMIC, on the right Y-axis)
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for parametric uncertainty, with the aim to identify in-
fluential parameters. This study evaluated the health and
economic effects of potential maternal RSV vaccines and
monoclonal antibodies for infants in 72 current and
former Gavi-eligible countries. We estimated that the
annual disease burden in these 72 countries is substan-
tial, including 20.8 million RSV cases, 1.8 million hos-
pital cases, and 40 thousand deaths, with average total
direct costs exceeding 600 million USD. We found that
the maternal strategy would be the optimal strategy
given a price of 3 USD per dose at a WTP value greater
than 3000 USD in most countries (range 1000–3500
USD) per DALY averted, whereas the mAb strategy
would be optimal given a price of 6 USD per dose at a
WTP value greater than 6000 USD (range 3500–8000
USD) per DALY averted. At these WTP values, the re-
sults are surrounded by large uncertainties mainly
caused by uncertainty around RSV incidence, mortality,
and especially RSV hospitalisation rates. At lower WTP
values (below 2500 USD per DALY averted), we are
more than 75% certain that no intervention is optimal
for the majority of countries. Hence, despite the notable
burden of RSV in early life, the short-lived protection of
the potential tools indicates that any prophylaxis would
have to be competitively priced in order to be consid-
ered cost-effective in Gavi-eligible settings.
To date, there is no licensed RSV vaccine (for mothers
or children) nor single-dose mAb, and the interventions’
duration of protection is unknown. An additional month
of protection was assumed for the mAb versus the ma-
ternal vaccination strategy, which is consistent with the
assumptions in the Gavi RSV investment case [31]. If
mAb would offer the same efficacy with a shorter dur-
ation of protection, but at a higher price than the mater-
nal vaccine, then mAb would simply be dominated by
the maternal vaccination strategy, irrespective of willing-
ness to pay. For both the maternal vaccination and mAb
strategies, simplified ‘all or nothing’ assumptions on dur-
ation of protection were made, where we assumed no
waning of protection up to the end of the period of pro-
tection, at which point protection drops to zero. We also
assume the same duration of illness for both non-
vaccinated and vaccinated children. The reason for such
assumptions is that the duration of protection is
Fig. 6 Scenario analysis: the efficacy of the interventions and its impact on the optimal strategy.
The optimal strategy is indicated by the colours (the current strategy is no intervention), and our certainty is indicated by the sizes of the markers.
Countries are ranked by RSV incidence rate (ordered from high to low on the left Y-axis [incidence per 1000 person-year in brackets]) and
stratified by income group (LIC or LMIC, on the right Y-axis)
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unknown. Hence, sensitivity analyses were performed
(Additional file 1). In this analysis, the focus is on esti-
mating the disease burden, given the currently available
data, and in identifying the main data gaps to fill (be-
sides information on the intervention tools) in order to
reduce decision uncertainty about interventions (defined
according to simple characteristics). Given a modelled
period of protection, this simplification—without waning
immunity—is likely to result in an overestimation of dis-
ease averted from these interventions, ceteris paribus.
The most advanced candidate is the maternal RSV
vaccine (NCT02624947) developed by Novavax. Unfor-
tunately, its phase 3 randomised controlled trial did not
demonstrate efficacy against its primary endpoint (med-
ically significant RSV LRTI), but it showed significant ef-
ficacy against one of its secondary endpoints
(hospitalisation) [6]. In order to maximise the informa-
tion provided by our simulations, we not only modelled
an extensive range of scenarios based on efficacy inter-
vention and price ranges (while accounting for all para-
meterised uncertainty), but we also modelled a scenario
using currently available peer-reviewed data on the
Novavax maternal vaccine (while accounting for all para-
meterised uncertainty, including wide uncertainty inter-
vals for efficacy against the primary and secondary
endpoints; see Additional file 1) [6]. However, additional
phase 3 trial data of this vaccine were presented at a re-
cent international conference [32]. These new per-
protocol post hoc analyses were interpreted by Novavax
as indicating their maternal vaccine is effective against
the broad endpoint of all-cause pneumonia (i.e. not just
RSV LRTI) among infants. Clearly, if the RSV interven-
tions (maternal vaccine or mAb) would offer such add-
itional protection, its value would greatly increase. This
remains as yet a controversial result—especially since
the same trial failed to demonstrate significant efficacy
against its FDA-prescribed primary endpoint—that
needs to be confirmed by thorough peer review. In view
of potential confounders influencing the broad endpoint
of ‘any medically significant LRTI’, it is important to es-
tablish at least whether (a) randomisation accounted for
comparable within-household and community vaccin-
ation status against influenza, pneumococcus, and Hae-
mophilus influenzae type b in both arms of the trial; (b)
Fig. 7 Scenario analysis: the protection duration of the interventions and its impact on the optimal strategy.
The optimal strategy is indicated by the colours (the current strategy is no intervention), and uncertainty is indicated by the sizes of the markers.
Countries are ranked by RSV incidence rate (ordered from high to low on the left Y-axis [incidence per 1000 person-year in brackets]) and stratified by
income group (LIC or LMIC, on the right Y-axis)
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these observations hold in the different country sites of
the trial; and (c) to which extent this is observed for out-
patient versus inpatients. We therefore opted not to ex-
plore the ramifications of these potential benefits in
additional scenario analyses in the current paper. Never-
theless, our extensive sensitivity analyses on efficacy,
waning, and price improve our understanding of the
cost-effectiveness of new RSV interventions. Therefore,
this type of analysis can inform vaccine developers’
product portfolio development, as well as decision-
makers and their advisors’ planning activities.
When WTP values are less than 1000 USD per DALY
averted, there is little uncertainty, given the product
characteristics we explored, that current practice is opti-
mal, and the resources are better spent on other inter-
ventions in these countries. If WTP values above 1000
USD and 3500 USD are considered acceptable, the ma-
ternal and mAB strategies, respectively, are increasingly
likely to become the optimal strategies. This last result is
however surrounded by much uncertainty. Hence, it
would be valuable to obtain more evidence on RSV inci-
dence, mortality rate, and especially hospitalisation prob-
ability. Of course, a refined understanding of the
features of any RSV prophylaxis would go a long way in
reducing the uncertainty around the optimal interven-
tion. However, community-based incidence studies, even
those undertaken prior to the implementation of RSV
prophylaxis, could also play a role in reducing the uncer-
tainty around the question of cost-effectiveness. Accord-
ing to our analysis, the importance of community-based
incidence studies, as opposed to hospital-based inci-
dence studies, cannot be stressed enough; the probability
of cases in the community that are hospitalised is one of
the most valuable parameters that we could study, and
this parameter cannot be estimated from any of the 76
hospital-based incidence studies that are documented in
Shi et al. (as they lack any information on the incidence
burdening the community in which the studies were set)
[2]. Moreover, the hospital-based case-fatality ratios can-
not reflect the overall RSV-associated deaths in LIC and
LMIC settings. We calculated the overall RSV-associated
death rates based on adjustment factors derived in Shi
et al. from only three studies in LMIC, as no country-
specific data is available. The adjustment factor of 2.2
(with uncertainty interval of 1.5–2.9) was used for all
countries to country-specific hospital case-fatality rates
in order to estimate country-specific RSV community
deaths. In countries where relatively fewer RSV-associated
ALRI cases seek health care, this factor is likely to be
higher and vice versa. It is therefore highly likely that
community RSV deaths were underestimated for LIC. In
our EVPPI analysis, this adjustment factor is one of the
top influential factors for this analysis. Hence, in addition
to the importance of the burden information per se for
policy-makers, studies on RSV-associated community
deaths can also provide highly useful information for
cost-effectiveness analysis.
To the best of our knowledge, this is the first multi-
country, multi-intervention cost-effectiveness analysis
for childhood prophylactic interventions against RSV in
LIC and LMIC settings. Two modelling studies applied
Kenyan data to understand the impact of RSV vaccin-
ation in low-income settings. Poletti et al. evaluated sev-
eral prevention strategies, including maternal, paediatric
(at 3 months), and school-age vaccination. They pre-
dicted a 30% reduction in RSV infant infection via ma-
ternal vaccination, which is very similar to our
prediction [26]. Additionally, Kinyanjui et al. used a dy-
namic transmission model to investigate the health im-
pact of vaccinating older children when natural maternal
immunity has waned (5–10months) on infants, which is
a different research question [33].
This analysis has several other strengths: firstly, we re-
estimated the age-specific disease incidence on a per-
month basis using detailed data presented in a published
systematic review and we used model-based estimates of
the total country-specific burden in all 72 countries.
Next, rather than estimating one region-level cost of ill-
ness [34], we estimated country-specific costs using a
simple method that leveraged the existing literature on
pneumonia costs in combination with the WHO-
CHOICE costs to capture the country-to-country vari-
ation in costs. Secondly, we accounted for parameter un-
certainty in a probabilistic way and performed extensive
scenario analyses to assess the impact of uncertainty in
parameters that have multiple and complex effects on
the outcomes and costs of RSV. We also plotted the
overall trends and impact of different assumptions in
both current disease trends and potential implementa-
tion programmes. Thirdly, this analysis includes a value
of perfect information analysis to inform data collection
prioritisation both for countries and vaccine developers
in order to improve the timeliness of the decision
process once the products become available. Moreover,
it also reflects the ‘full value of vaccines’ agenda from
the WHO that encourages evaluation of vaccine value
during the development phase so as to avoid vaccine
manufacturers bring unmarketable vaccines into late
stage development or onto the market [35]. Finally, the
investment decisions of RSV interventions need to be
made both at the country and multi-country level (i.e.
through the WHO policy recommendations and Gavi fi-
nancial support). Since the WHO has explicitly discour-
aged the use of GDP per capita as a benchmark of the
incremental direct costs that a country should be willing
to pay to gain a QALY, or avert a DALY [36], we present
and interpret this complex analysis across different WTP
levels for various stakeholders. Consequently, the
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decision of the optimal strategy can be made based on
any WTP threshold within the wide range we explored.
Within each country, the coverage is likely to differ be-
tween different intervention strategies, whereas we as-
sumed BCG infant coverage for all strategies in the
interest of parsimony. Since this is a static model and
marginal intervention costs are assumed to be directly
proportional to doses administered, the coverage will
only impact the overall disease burden averted and not
the cost-effectiveness [37]. Although the maternal tet-
anus vaccination programme is available in a few coun-
tries under the tetanus elimination goal, the maternal
vaccination programme is not yet well established in
most of the 72 countries, representing an implementa-
tion challenge. The maternal vaccine could be adminis-
tered during an ANC visit. The current WHO
recommendation for maternal acellular pertussis vaccin-
ation is in the second or third trimester and at least 15
days before birth [38]. With the ANC visit coverage and
frequency (ranging from 4.3% in Somalia to 96% in
Armenia, at least four times throughout pregnancy) in
LIC and LMIC countries [10], maternal immunisation
coverage is unlikely to achieve the BCG coverage level,
implying we may have overestimated the impact of this
strategy on disease burden.
The maternal strategy captures only the health benefit
to infants in our model; however, the potential benefits
to the mothers and household contacts are not consid-
ered, as the burden of RSV in childbearing-age females
and the RSV vaccine duration of protection in adults are
both unknown. From the literature, the highest disease
burden of RSV is in the very young age group; therefore,
the health benefits to the mothers or contacts are un-
likely to have a significant impact on the overall results.
Additionally, there may be uncaptured psychosocial ben-
efits to caregivers in improved child survival and health.
Future research could consider factors in RSV epidemi-
ology that were beyond the scope of the current model’s
structure and the data available. The impact of transmis-
sion dynamics could capture the effects of prophylaxis
on the contacts of the mother or the child, but the exist-
ent data on disease dynamics precludes the development
of a dynamic model applicable to all settings in our ana-
lysis. Relatedly, our model assumes that cases averted on
a certain month are averted altogether, rather than
shifted to later ages, potentially favouring the case for
RSV prophylaxis. However, RSV incidence peaks at a
very young age in most countries and younger cases are
more severe than older cases (in terms of the need for
hospitalisation and the probability of death); hence, we
believe that a slight increase in incidence in children
over 6 months of age would not represent a displace-
ment in time of hospitalised/fatal cases, since older cases
are less likely to result in hospitalisation or death.
The seasonality of RSV is not considered in this evalu-
ation as the analysis includes countries in several conti-
nents with differing seasonal patterns. It is challenging
to identify the start and peak of RSV seasons in the ab-
sence of good surveillance in these countries. Cromer
and colleagues explored a seasonal RSV vaccination
programme in the UK, showing that targeting births in
particular months of the year might be more efficient
than a year-round programme [12]. The implementation
challenges of such a seasonal programme in low- and
middle-income countries are currently not well docu-
mented. For instance, young infants born before the
RSV season would still be vulnerable for severe RSV dis-
ease, but they may be difficult to reach with a seasonal
programme. One way to interpret our results in light of
a seasonal programme is by assuming that this would re-
quire fewer doses for the same (or similar) effectiveness.
For instance, if only half of pregnant women/newborns
would need to be targeted to protect them through an
RSV season occurring over part of the year, then all
WTP changepoints (where the optimal strategy of choice
changes) in our analyses would be approximately halved.
This analysis also has a few additional limitations, but
all render our analysis more conservative (we bias
against implementation and the potential misuse of
existing resources). The indirect effects on disease trans-
mission are ignored, which in the case of the strategies
considered here would likely represent an underestima-
tion of the benefits. The fixed implementation costs (i.e.
campaign, establishing a new vaccination visit instead of
using existing platform) were not considered, although
the intervention cost (procurement and delivery costs)
per dose was included as a variable in our model. If one
strategy would require higher fixed costs than another, it
may impact the ICERs and therefore the choice of the
optimal strategy. Direct non-medical costs (e.g. transpor-
tation) and indirect costs (e.g. productivity losses) are
not included in our analyses due to a lack of data.
Uncertainty around the proportion of RSV cases not
seeking health care was not explored due to insufficient
information. Interventions targeting high-risk groups
only (i.e. preterm, bronchopulmonary dysplasia, and
chronic heart disease) are not considered as these groups
are unlikely to be identified easily in these countries.
This analysis focuses on the RSV-associated ALRI as de-
fined in the systematic reviews [1, 2]. Other RSV-
associated acute infections are not included (i.e. upper
respiratory tract infection, otitis media). Longer-term
chronic conditions, such as recurrent wheezing and
asthma, are also not considered yet due to limited evi-
dence that these are influenced directly by RSV infections;
there is also a paucity of health and cost burden data on
these conditions for the countries considered here. Fur-
thermore, a recent study showed that current RSV
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prophylaxis has a limited impact on the reduction of these
conditions [39]. Evidence about the causal association be-
tween RSV and these conditions is still emerging.
Conclusion
RSV interventions could prevent substantial RSV-
associated cases, hospital admission, and deaths, conse-
quently averting sizable DALYs and treatment costs.
However, if the extent and duration of effectiveness of
maternal vaccine and monoclonal antibody RSV strat-
egies turn out in line with our assumptions, these inter-
ventions may become optimal compared with current
practice only at high willingness to pay values per DALY
averted and/or competitive per-dose prices. In order to
assess their relative cost-effectiveness, information on
the nature, level, and duration of protection these inter-
vention options confer would be required. The current
analysis indicated that more empirical research on the
proportion of all RSV cases that are hospitalised, RSV
incidence, and case-fatality ratios in hospitals and the
community would be highly valuable to reduce decision
uncertainty when detailed clinical trial data eventually
become available.
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